IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.
On May 2, 2019, IRIDEX Corporation issued a press release discussing its financial results for its first fiscal quarter of 2019, which ended on March 30, 2019.The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
IRIDEX CORP Exhibit
EX-99.1 2 irix-ex991_7.htm EX-99.1 irix-ex991_7.htm Exhibit 99.1 IRIDEX Announces 2019 First Quarter Financial Results MOUNTAIN VIEW,…
To view the full exhibit click here
About IRIDEX CORPORATION (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.